Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1221-1240 of 1,738 trials

Cemiplimab for High-Risk Skin Cancer

We are studying whether the immunotherapy Cemiplimab can help prevent cancer recurrence in patients with high-risk stage III/IV skin cancer who can undergo surgery.

Cutaneous Squamous Cell CarcinomaSurgically Resectable, High Risk Stage III/IV Cutaneous Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDermatologyOncology

Ulcerative Colitis: SAR442970 Study

We are investigating how effective different doses of SAR442970 are for adults with moderate to severe ulcerative colitis. The study aims to see if it can help improve symptoms and overall quality of life.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesGastroenterology

New Method for Umbilical Vein Catheterization in Newborns

We are studying a new technique for umbilical vein catheterization to see if it helps newborns in circulatory arrest receive faster and more effective resuscitation. This trial compares the new method with standard practices in the delivery room.

Cardiorespiratory Arrest at Birth in Full-Term Newborns≤3 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesInternal MedicinePediatrics

Myelofibrosis: Roginolisib with Ruxolitinib

We are studying the safety and tolerability of roginolisib combined with ruxolitinib for patients with myelofibrosis who haven't responded to other treatments. The trial also looks at symptom improvement and changes in spleen size.

MyelofibrosisSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Melanoma, Breast Cancer, and Head & Neck Cancer: Contrast-Enhanced Ultrasound Study

We are exploring whether contrast-enhanced ultrasound can better locate sentinel nodes during surgery compared to the current standard method. This study aims to improve detection and potentially predict if the nodes are cancerous.

Breast CancerMelanomaHead and Neck Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncologyOtolaryngology

Acute Myeloid Leukemia: Venetoclax and Azacitidine Study

We are comparing a new treatment combination with standard chemotherapy for patients with newly diagnosed acute myeloid leukemia and NPM1 mutations. The goal is to see if this new approach is more effective and easier to tolerate.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Grass Allergy: Vitamin D Enhanced Immunotherapy

We are studying whether combining intralymphatic immunotherapy with vitamin D helps improve allergy symptoms in people with moderate to severe grass allergies during pollen season.

Allergic Rhinitis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesAllergology

Multiple Myeloma: HDP-101 Treatment Study

We are testing a new treatment called HDP-101 for patients with relapsed or refractory multiple myeloma. The study aims to find a safe dose and evaluate how well it works.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Filgrastim for Severe Bullous Drug Eruptions

We are studying whether Filgrastim can help patients with severe drug reactions like Stevens-Johnson syndrome. The goal is to see if it slows disease progression and improves recovery compared to standard treatment alone.

Stevens Johnson SyndromeLyell Syndrome>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsInvestigational MedicinesDermatology

Congenital Hyperinsulinism: HM15136 Treatment Study

We are evaluating a new treatment for children with congenital hyperinsulinism to see if it is safe and helps reduce low blood sugar events. This study includes children aged 2 years and older.

Congenital Hyperinsulinism≤3 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyPediatrics

Epithelioid Malignant Pleural Mesothelioma: Atezolizumab and WT1/DC Vaccine

We are studying the safety and effectiveness of adding a new treatment to standard chemotherapy for patients with epithelioid malignant pleural mesothelioma. This trial aims to see if the combination improves treatment outcomes.

Malignant Pleural Mesothelioma6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology

Ovarian Cancer: Pembrolizumab with Chemotherapy

We are studying a new treatment combining pembrolizumab with chemotherapy for patients with small cell ovarian carcinoma. The goal is to see how well this combination works and to evaluate its safety.

Ovarian Small Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Rhizarthrosis: Autologous Stromal Vascular Fraction Injection

We are studying the safety and effects of an injection using your own stem cells for treating rhizarthrosis. This trial will help us understand its impact on pain and joint function over several months.

Rhizarthrosis (Thumb Arthritis)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOrthopedics and TraumatologyRheumatology

Rectal Cancer: NanoEcho Imaging Study

We are exploring a new imaging method for examining rectal lymph nodes in healthy volunteers and rectal cancer patients. The goal is to assess safety and improve detection of lymph node involvement.

Rectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Pancreatic Cancer: GEMBRAX and FOLFIRINOX Treatment Study

We are exploring a new treatment sequence for patients with locally advanced pancreatic cancer to see if it improves outcomes and tolerability. This study will help us understand its effects on survival and quality of life.

Non-resectable Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Breast Cancer: Trastuzumab-Deruxtecan Treatment Study

We are investigating if switching to a new drug can help patients with HR+ HER2 low metastatic breast cancer who are not responding well to standard therapy. This study aims to find out if this change improves survival and response rates.

Metastatic Breast CancerEfficacy phase (II)No PlaceboInvestigational MedicinesEndocrinologyOncology

Lower Risk MDS: Luspatercept and EPO Combination Study

We are studying a new treatment combining luspatercept with EPO for patients with lower risk MDS who haven't responded to previous therapies. The goal is to see if this combination helps improve blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Inflammatory Bowel Disease: Risankizumab-800CW Imaging Study

We are investigating the safety and effectiveness of a new imaging agent for patients with Inflammatory Bowel Disease. This study aims to improve how we visualize drug targeting and inflammation in the intestines.

Inflammatory Bowel Disease (IBD)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyInfectious Diseases

CIDP: NVG-2089 Treatment Study

We are evaluating the safety and effectiveness of NVG-2089 for individuals with Chronic Inflammatory Demyelinating Polyneuropathy. This study aims to find out if it can help improve symptoms and overall health.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

MELAS: Testing Zagociguat

We are studying the investigational drug zagociguat to see if it helps reduce fatigue and improve thinking skills in people with MELAS. The trial also looks at its safety and effects on muscle weakness and memory.

MELAS Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNeurology